8-K: Channel Therapeutics to Merge with Ligand's Pelthos Therapeutics, Aiming to Launch ZELSUVMI for Molluscum Contagiosum

Channel Therapeutics Corporation will merge with Ligand Pharmaceuticals' Pelthos Therapeutics, supported by a $50 million private placement, to focus on commercializing ZELSUVMI for molluscum contagiosum.

Summary

• Channel Therapeutics Corporation (Channel) and Ligand Pharmaceuticals Incorporated (Ligand) have announced a definitive merger agreement where Channel will acquire Ligand's subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. (collectively Pelthos).
• The merger will be supported by a $50 million private placement led by Murchinson.
• Upon completion, the combined company will be named Pelthos Therapeutics Inc. and will trade on the NYSE American under the ticker PTHS.
• The primary focus will be on commercializing ZELSUVMI (berdazimer) topical gel, 10.3%, an FDA-approved treatment for Molluscum contagiosum (molluscum) in patients one year and older.
• ZELSUVMI is the first and only prescription therapy for molluscum infections approved for at-home use.
• The combined company will also retain Channels existing NaV 1.7 development programs for chronic pain, eye pain, and post-surgical nerve blocks.
• Ligand will invest $18 million, and the Investor Group will invest $32 million, totaling $50 million in the combined company.
• Post-merger, Channel stockholders are expected to own approximately 8%, Pelthos stockholders approximately 34%, and private placement investors approximately 58% of the combined company.
• The transaction is expected to close in the summer of 2025, pending customary closing conditions.

Sentiment

Score: 8

Explanation: The document expresses a positive outlook due to the merger, the potential of ZELSUVMI, and the financial backing from investors. The management comments are optimistic, and the focus on addressing unmet medical needs contributes to a favorable sentiment.

Positives

• ZELSUVMI is an FDA-approved drug with a novel designation, offering a first-in-class at-home treatment for Molluscum contagiosum.
• The merger provides Channel shareholders with the potential for near-term revenue generation and expanded capitalization.
• The combined company will retain Channels NaV 1.7 programs, offering potential for future growth in pain management.
• The $50 million private placement provides significant financial backing for the commercial launch of ZELSUVMI.
• Pelthos intends to execute on a $25M venture debt term loan and $7M receivables line prior to closing, which would increase cash at closing to $37M.

Risks

• The transaction is subject to customary closing conditions and may not be completed.
• The combined company's success depends heavily on the commercial success of ZELSUVMI, which has not yet launched.
• The company will require substantial additional capital to finance future operations.
• The company faces competition from companies with greater resources.
• The company's expectations regarding cash runway and data inflection points are based on assumptions that may prove untrue.
• The company is in advanced discussions on the acquisition of a second FDA-approved, highly complementary pediatric infectious disease product that can be acquired for an estimated $4.4M up front with $7.2M of contingent milestones and royalties, however, the parties have not entered into any definitive agreement for this potential acquisition and there can be no assurance that it will be consummated.

Future Outlook

The combined company will focus on commercializing ZELSUVMI and advancing Channel's NaV 1.7 programs, with existing capital resources expected to fund operations until cash-flow breakeven in 2027, assuming entry into the term loan and receivables line.

Management Comments

• Todd Davis, CEO of Ligand, stated that the transaction presents a compelling opportunity to launch a commercial-ready product and deliver value to shareholders.
• Frank Knuettel II, CEO of Channel Therapeutics, expressed excitement about the merger and the potential for near-term revenue generation and expanded capitalization.
• Scott Plesha, CEO of Pelthos, highlighted the significant unmet medical need for an easy-to-use treatment option for molluscum and the potential of ZELSUVMI to address this need.

Industry Context

The announcement highlights the growing demand for innovative and convenient treatments for common skin infections like Molluscum contagiosum, and the potential for targeted therapies to address chronic pain.

Comparison to Industry Standards

• ZELSUVMI's at-home administration differentiates it from existing in-office treatments like cantharidin, potentially offering a more convenient and less invasive option for patients.
• The NaV 1.7 programs target a validated pain pathway, aligning with industry efforts to develop non-opioid alternatives for pain management.
• The $50 million private placement is a significant investment, comparable to funding rounds for other emerging biopharmaceutical companies focused on commercializing novel therapies.

Management Changes

Stakeholder Impact

• Shareholders of Channel Therapeutics will receive shares in the combined company, with the potential for increased value due to the commercialization of ZELSUVMI.
• Employees of both Channel Therapeutics and Pelthos Therapeutics will be integrated into the new company, with potential changes in roles and responsibilities.
• Patients with Molluscum contagiosum will have access to a new at-home treatment option, potentially improving their quality of life.
• Ligand Pharmaceuticals will receive a 13% royalty on worldwide sales of ZELSUVMI.

Next Steps

• The transaction is subject to customary closing conditions and is expected to close in the summer of 2025.
• Pelthos intends to execute on a $25M venture debt term loan and $7M receivables line prior to closing.
• The combined company will focus on commercializing ZELSUVMI and advancing Channel's NaV 1.7 programs.

Key Dates

Keywords

ZELSUVMI, Molluscum contagiosum, Merger, Channel Therapeutics, Pelthos Therapeutics, Ligand Pharmaceuticals, Private placement, NaV 1.7, Commercialization, FDA approval